Neurology News
Latest developments in neurological diseases
Senescence of T cells and organ aging.
Senescence of T cells is strongly linked to organismal aging through two interconnected processes: chronic low-grade inflammation and reduced immune surveillance of senescent cells. T cells are partic
Artificial neurons successfully communicate with living brain cells
Engineers at Northwestern University have taken a striking leap toward merging machines with the human brain by printing artificial neurons that can actually communicate with real ones. These flexible
Public Notification: Slimina contains hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Slimina, a product promoted and sold for weight loss on various websites, including www.effectivehealthyproducts.com, and
Search for Pharmaceutical Quality Documents
FDA provides resources on pharmaceutical quality topics, including information on regulations, guidance documents, and compliance programs in a searchable and filterable table format
Drug Compliance Programs
FDA compliance programs provide guidance and instructions to FDA staff for obtaining information to help fulfill agency plans in the specified program area.
Blood-Based Biomarker Revolution in Neurology: NfL, GFAP, and p-tau217
Alzheimer, MS, and ALS diagnosis and monitoring becoming possible with a simple blood test. NfL, GFAP, and p-tau217 entering clinical practice.
SAINT Protocol: 79% Remission in 5 Days — rTMS Revolution in Treatment-Resistant Depression
Stanford University's accelerated iTBS protocol (SAINT) breaks new ground in treatment-resistant depression.
BTK Inhibitors New Hope for Progressive MS: HERCULES and FENhance Trial Results
Tolebrutinib and Fenebrutinib promise as the first drug class crossing the blood-brain barrier for progressive MS treatment.
Tofersen: First Gene-Targeted ALS Therapy Brings Hope for SOD1 Patients
FDA-approved Tofersen (Qalsody®) provides neuroprotection by reducing neurofilament levels in SOD1-ALS patients.
GLP-1 Agonist Lixisenatide Slowed Motor Progression in Parkinson's Disease (NEJM 2024)
Diabetes drug Lixisenatide significantly slowed motor progression in Parkinson's disease. LIXIPARK trial published in NEJM.
Anti-Amyloid Revolution in Alzheimer's: Lecanemab and Donanemab Receive FDA Approval
Landmark in Alzheimer's treatment: Two new anti-amyloid antibody drugs receive FDA approval. Slowing cognitive decline by 27-35%.
Scientists just found a hidden “drain” inside the human brain
A hidden waste-removal pathway in the brain has finally been caught in action. Using cutting-edge MRI scans, researchers discovered that fluid flows along the middle meningeal artery in a slow, lympha
FDA Approval: New Guidance Documents
Xarelto is a medication used to prevent and treat blood clotting disorders.
MigrenTakip+ App Now Available on Apple App Store
MigrenTakip+ app, developed by Prof. Dr. Burhanettin Uludağ, is now available for free on the Apple App Store for physicians and patients. Track your migraine attacks digitally.
FDA Approves Inebilizumab for Myasthenia Gravis Treatment
The anti-CD19 monoclonal antibody inebilizumab received FDA approval for the treatment of generalized acetylcholine receptor or MuSK-positive myasthenia gravis.
McDonald Criteria for Multiple Sclerosis Diagnosis Updated: 2024 Revision
The McDonald criteria for MS diagnosis underwent significant changes. The optic nerve was added as a fifth anatomic region and new biomarkers were incorporated.
AHA/ASA Updates Guideline for Early Management of Acute Ischemic Stroke
The American Heart Association and American Stroke Association published updated guidelines for early management of acute ischemic stroke with important changes expanding treatment access.
Extended Time Window for Tenecteplase in Acute Ischemic Stroke: Two New Trials
The TRACE-5 and OPTION trials showed that intravenous thrombolysis with tenecteplase 4.5-24 hours after stroke onset yielded favorable outcomes in selected patients.
Alpha-Synuclein Biomarker Tests in Parkinson Diagnosis: Expert Review
A comprehensive expert review on commercially available alpha-synuclein biomarker tests for Parkinson disease diagnosis has been published.
Occipital Nerve Block Found Effective in Acute Migraine Attacks
A randomized controlled trial showed that greater occipital nerve block provides significant pain reduction in severe acute migraine attacks resistant to standard treatment.
Regular Caffeine Consumption May Lower Dementia Risk: Large Cohort Study
Results from two large prospective cohort studies revealed that consuming 2-3 cups of coffee per day is associated with a significant reduction in dementia risk.
Semaglutide Does Not Slow Alzheimer Disease Progression: Phase 3 Results
Two large Phase 3 clinical trials of the GLP-1 receptor agonist semaglutide showed that two years of treatment did not slow disease progression in patients with early-stage Alzheimer disease.
Effects of erenumab on migraine aura frequency: a REFORM study
Anti-CGRP monoclonal antibody erenumab may reduce migraine aura frequency, as shown by the REFORM study.
Novel Drug Approvals for 2025
Innovative drugs approved by FDA in 2025 mean new treatment options for patients and advances in health care.
Vivid dreams may be the secret to deeper, more restful sleep
Researchers found that immersive dreaming can actually make sleep feel deeper and more refreshing.
Migraine Prevalence Study in Turkey: 1 in 5 Women Affected
A comprehensive study by the Turkish Neurological Society across 15 provinces revealed that migraine prevalence in Turkey is higher than expected.
AI-Powered Seizure Prediction in Epilepsy: New Wearable Device
MIT inventors have developed a new AI-powered wearable device that can predict epileptic seizures an average of 45 minutes in advance.
Daily 30-Minute Walking Proven to Reduce Dementia Risk by 40%
A large-scale study published in The Lancet confirmed that regular physical activity significantly reduces dementia risk.
Importance of Early Treatment in Childhood Epilepsy: New Guideline
ILAE's new guideline emphasizes that early and aggressive treatment in childhood epilepsy improves long-term outcomes.
Gut-Brain Axis in Neurological Diseases: New Evidence for Microbiome Therapy
A review in Nature Neuroscience shows gut microbiome plays a role in multiple neurological diseases including migraine, epilepsy and dementia.
Lecanemab Receives Approval in Turkey: Early Stage Alzheimer Treatment
Amyloid plaque-clearing antibody therapy lecanemab has been approved by TITCK for early-stage Alzheimer's disease.
Brain Mechanism of Migraine Aura Imaged for First Time
Harvard and MIT researchers have successfully imaged how migraine aura spreads in the brain for the first time. Findings open the door to new treatment targets.
Turkey Neurology Week 2026: Importance of Awareness
Turkish Neurological Society launched a free neurological examination campaign nationwide as part of 2026 Neurology Week.
Alzheimer Blood Test Opens Breakthrough in Early Diagnosis
A newly developed blood test can detect Alzheimer's disease up to 15 years before symptoms appear by measuring phosphorylated tau 217 protein.
FDA Approves New CGRP Antagonist Drug for Chronic Migraine
The FDA has approved a new generation CGRP receptor antagonist for chronic migraine treatment. The drug promises hope for patients experiencing 15 or more migraine days per month.
2026 European Headache Congress: Key Findings
New studies presented at the Barcelona congress confirmed the efficacy of neural stimulation methods in migraine treatment.
Effect of Cognitive Games on Mild Cognitive Impairment: Meta-Analysis Results
A meta-analysis covering 42 studies revealed that digital cognitive exercises improve attention and working memory in mild cognitive impairment.
Next-Gen Neurostimulation Device Effective in Three Diseases
Programmable neurostimulation device shows successful results in clinical trials for migraine, epilepsy and mild cognitive impairment.
EMA Approves Cenobamate for Drug-Resistant Epilepsy
The European Medicines Agency has approved cenobamate for the treatment of drug-resistant focal epilepsy.
Images: Servier Medical Art (CC BY 4.0) and Unsplash